Yokogawa Technology Selected for the Japan Science and Technology Agency's Next-generation Technology Transfer Program

Tokyo, Japan - August 5, 2014

Yokogawa Electric Corporation announces that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). NexTEP was created to promote efforts by companies to find practical applications for the technologies (including those covered by patents) and research findings of universities and public research institutions.

Through this undertaking, JST aims to develop a new drug-discovery support system that will integrate a single-cell mass spectrometry^*1 method developed by the RIKEN Quantitative Biology Center's Laboratory for Single Cell Mass Spectrometry with high-speed imaging and high-precision positioning technologies that Yokogawa has developed for its confocal scanner units and drug-discovery support devices^*2.

For the development of new drugs, multiple cells are typically ground to analyze intracellular metabolism and thereby verify the efficacy and side effects of a particular candidate drug. A drawback of this technique is that molecular changes in individual cells cannot be analyzed in sufficient detail. In addition, large numbers of animal and human cells are required.

With this new system, JST aims to clarify how molecules of a candidate drug reach a specific cell and the changes that take place there. Single-cell mass spectrometry is a technique for the analysis of target molecules that have been suctioned out from individual cells as they are being observed under a microscope. The system that is to be developed will speed up this process by automating the identification of cells and molecules where unusual changes have taken place, and automatically capturing target molecules. In addition to speeding up analysis, this will reduce costs.

Yokogawa will work with RIKEN to develop a system that will accelerate the development of new drugs by enabling the quick and precise analysis of the effect that candidate drugs have on intracellular metabolism.

*1 Single-cell mass spectrometry
A method whereby cell molecules are suctioned out using a microfine glass tube (nanospray chip), ionized with an ionizing organic solvent, and analyzed (to identify type and amount) using a mass spectrometer. Performed under a microscope, this method is fast and the analysis results are highly precise. While a large sample is needed with conventional methods, this analysis method requires just one cell, and it can also quantify intermediate metabolites and trace metabolic pathways to final metabolites.

*2 Yokogawa's confocal scanner unit and drug-discovery support system
The confocal scanner is a scanning unit that focuses laser beams on individual points on a plane to acquire tomographic images of live cells at selected depths, without the need for slicing the sample. Thanks to its clear images and industry-leading imaging speed, Yokogawa's confocal scanner is widely used in research institutions around the world. The Yokogawa drug-discovery support system that incorporates this scanner unit is an automated testing tool that looks at cell functions, administers drug candidate compounds to cells, takes pictures of induced intracellular changes, and analyzes reactions. This system also leads the industry in screening speed and resolution.

 

About Yokogawa

Yokogawa's global network of 86 companies spans 56 countries. Founded in 1915, the US$4 billion company conducts cutting-edge research and innovation. Yokogawa is engaged in the industrial automation and control (IA), test and measurement, and other businesses segments. The IA segment plays a vital role in a wide range of industries including oil, chemicals, natural gas, power, iron and steel, pulp and paper, pharmaceuticals, and food. For more information about Yokogawa, please visit the company's website www.yokogawa.com